Inihibitors of mmune checkpoint molecules such as blocking antibodies against PD-1 and CTLA-4 are currently FDA approved and used routinely for the clinical management of cancer as monotherapeutic agents or in combination with other treatments (Twomey and Zhang, 2021) and many more are currently in clinical trials. The gene discussed is PDCD1; the disease is cancer.